Antigens and Antibodies for 2024-2025 Influenza Vaccine Strains Are Available Now!
On February 23rd, 2024, the World Health Organization (WHO) announced the recommendations for influenza vaccine composition for the 2024-2025 northern hemisphere influenza season. To support vaccine research, Sino Biological has released the recombinant antigens for 2024-2025 influenza vaccine strains.
With the world’s largest viral antigen collection, ProVir®, Sino Biological provides a range of recombinant influenza antigen products, including Hemagglutinin (HA), Neuraminidase (NA), and Nucleoprotein (NP) proteins from all WHO-recommended vaccine strains in recent years. A large collection of monoclonal antibodies against the flu antigens are also available to support the development of relevant assays and diagnostic kits.
Learn more about our recombinant antigens for 2024-2025 Influenza Vaccine Strains!
Building Expertise in Influenza Antigen and Antibody Development for Over 15 Years:
Pan Influenza A and B Antibodies
Influenza Vaccine Development and Production Solutions
600+ Influenza Virus Antigen Bank
Customized Viral Protein Production and Antibody Development through CRO
